Dismiss Modal
Elizabeth A. Beierle, MD

Elizabeth A. Beierle, MD

Pediatric General Surgery
Charles D. McCrary Chair in Pediatric Surgery

Office Locations

Professor of Surgery and Pediatrics, Surgical Director, Hepatobiliary Clinic

Education

  • Residency: University of Florida
  • Medical School: University of North Dakota
  • Fellowship: St. Christopher's Hospital for Children, Philadelphia, PA
  • Internship: Baylor College of Medicine
  • UnderGraduate: University of North Dakota

Board Certifications

  • American Board of Surgery (1970)
  • American Board of Surgery - Pediatric Surgery (1970)

Honors and Awards

Women Who Shape the State (2016), Top Doctors in Birmingham (2015-2017)

Special Interests

Dr. Bierle is an Associate Professor of Surgery Patient Care Emphasis: Pediatric surgical oncology, neonatal surgery, burn and trauma care Research: Dr. Beierle's research interest lies in the study of pediatric solid tumors, specifically the signal transduction pathways involved in neuroblastoma.

Interests

pediatric surgical oncology

Professional Organizations

FACS, FAAP, APSA, SUS, Southern Surgical, American Surgical

Publications

1. Regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem, 282:125 2. 53. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, Golubovskaya VM. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle, 9: 1005-15, 2010. 3. 66. Gillory LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM, Kelly V, Coleman JM, Markert JM, Gillespie GY, Friedman GK, Beierle EA. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLOS ONE, 8:e77753, 1-19, 2013. 4. Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA. Pre-clinical evaluation of a novel RXR agonist for the treatment of neuroblastoma. Molec Cancer Ther, 14:1559-1569, 2015. 5. Waters AM, Stafman LL, Garner EF, Mruthyunjayappa S, Stewart JE, Mroczek-Musulman E, Beierle EA. Targeting focal adhesion kinase suppresses the malignant phenotype in rhabdomyosarcoma cells. Trans Oncol, 9:263-272, 2016.